Tocilizumab Raises GI Risks in Rheumatoid Arthritis

(MedPage Today) -- Patients with rheumatoid arthritis (RA) who were treated with tocilizumab (Actemra) had twice the risk of gastrointestinal perforations than those on tumor necrosis factor (TNF) inhibitors, Swedish researchers reported.
Compared...